Literature DB >> 26143177

Lambert-Eaton myasthenic syndrome and prostatic adenocarcinoma.

Cecília Monteiro1, Isabel Moreira2, José Lopes Lima1,3, Ernestina Santos1,3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26143177     DOI: 10.1007/s10072-015-2315-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  6 in total

1.  Prostate carcinoma and the Lambert-Eaton myasthenic syndrome.

Authors:  B Delahunt; D A Abernethy; C A Johnson; J N Nacey
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome.

Authors:  Shin J Oh; Katsumi Kurokawa; Gwen C Claussen; Hewitt F Ryan
Journal:  Muscle Nerve       Date:  2005-10       Impact factor: 3.217

3.  Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome.

Authors:  B Têtu; J Y Ro; A G Ayala; N G Ordóñez; C J Logothetis; A C von Eschenbach
Journal:  Urology       Date:  1989-02       Impact factor: 2.649

Review 4.  Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.

Authors:  Maarten J Titulaer; Bethan Lang; Jan Jgm Verschuuren
Journal:  Lancet Neurol       Date:  2011-12       Impact factor: 44.182

Review 5.  Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome.

Authors:  P D Clouston; C B Saper; T Arbizu; I Johnston; B Lang; J Newsom-Davis; J B Posner
Journal:  Neurology       Date:  1992-10       Impact factor: 9.910

Review 6.  Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association.

Authors:  S K Agarawal; B R Birch; G F Abercrombie
Journal:  Scand J Urol Nephrol       Date:  1995-09
  6 in total
  1 in total

Review 1.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.